Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disease by itself has led to the development of new treatments. In this article, we discuss the pathophysiology of inflammation and focus attention on therapeutics targeting different inflammatory pathways of atherosclerosis and myocardial infarction. In atherosclerosis, colchicine is included in new recommendations, and eight randomized clinical trials are testing new drugs in different inflammatory pathways. After a myocardial infarction, no drug has shown a significant benefit, but we present four randomized clinical trials with new treatments targeting inflammation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865197PMC
http://dx.doi.org/10.3390/ph16010078DOI Listing

Publication Analysis

Top Keywords

inflammatory pathways
8
myocardial infarction
8
randomized clinical
8
clinical trials
8
anti-inflammatory drug
4
drug candidates
4
candidates prevention
4
prevention treatment
4
treatment cardiovascular
4
cardiovascular diseases
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!